Trial Profile
A phase III international, multi-center, prospective, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of nitric oxide synthase inhibition with tilarginine acetate injection in patients with cardiogenic shock complicating acute myocardial infarction, or the TRIUMPH trial
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tilarginine (Primary)
- Indications Cardiogenic shock; Myocardial infarction
- Focus Therapeutic Use
- Acronyms TRIUMPH
- 28 Mar 2007 Results have been published.
- 23 Oct 2005 New trial record.